CBN Explained: What the Evidence Really Says About Sleep and Other Potential Uses
Cannabinol, or CBN, is often marketed as a cannabis-derived sleep aid. But the scientific picture is more measured: CBN is a minor cannabinoid with plausible biological activity, limited human research, and no established medical use for insomnia or other conditions.
CBN is produced mainly when delta-9-tetrahydrocannabinol (THC) undergoes oxidation. Heat, light, oxygen, and time can accelerate this process, which is why older or poorly stored cannabis may contain more CBN than freshly harvested material. This is different from decarboxylation: heat converts tetrahydrocannabinolic acid (THCA) into THC, while the later breakdown of THC contributes to CBN formation.
Pharmacologically, CBN appears to interact weakly with the cannabinoid receptors CB1 and CB2, with considerably less activity at CB1 than THC. That helps explain why CBN is generally less intoxicating than THC, although “non-psychoactive” is too absolute. A 2026 randomized trial in 20 adults with diagnosed insomnia found that a 300-milligram dose produced modest subjective drug effects, while lower doses did not show the same pattern. Laboratory studies also indicate that CBN can affect transient receptor potential channels, including TRPA1, but the significance of these interactions in people remains uncertain.
The strongest consumer claim surrounding CBN is that it causes sleepiness. Earlier human studies from the 1970s and 1980s generally found little evidence that CBN alone produced substantial drowsiness, although some suggested it might enhance the sedating effects of THC. A 2021 review of the clinical evidence concluded that published research was too limited and inconsistent to support broad sleep-related marketing claims.
More recent research has begun to test CBN more rigorously. In the 2026 randomized, placebo-controlled insomnia trial, participants received either 30 milligrams or 300 milligrams of CBN for one night. Neither dose significantly reduced the primary outcome, wake time after sleep onset. The higher dose did shorten the time needed to fall asleep and improved some subjective sleep measures, but the study was small, assessed only a single night, and cannot establish that CBN is an effective long-term treatment for insomnia.
Evidence for other potential uses is even more preliminary. In a mouse model of amyotrophic lateral sclerosis, CBN delayed the onset of symptoms by more than two weeks but did not extend survival; the study was conducted in transgenic mice, not people. CBN has also shown activity against MRSA biofilms in laboratory experiments, including a 2025 study in which it reduced bacterial viability. These findings may help guide drug development, but they do not show that CBN products can treat infections.
Similarly, CBN has inhibited the growth of cancer cells in cell cultures and reduced tumor growth in some animal experiments. Other laboratory work has found that CBN can reduce keratinocyte proliferation and inflammatory signaling, providing a possible rationale for investigating it in conditions such as psoriasis. A 2024 study in human keratinocytes reported anti-inflammatory effects involving TRPV1 and the endocannabinoid system. None of these results demonstrates a cancer treatment or proven therapy for psoriasis.
Claims about appetite stimulation and pain relief should also be treated cautiously. Cannabis research has often focused on THC or mixtures of cannabinoids, so results involving those compounds cannot automatically be attributed to CBN. For now, the most defensible conclusion is that CBN is a biologically active, weakly intoxicating cannabinoid that merits further study—not that it is a proven sleep aid, analgesic, appetite stimulant, antibiotic, or anticancer medicine.
